002653 海思科
已收盘 07-15 15:00:00
资讯
新帖
简况
海思科(002653.SZ):创新药HSK47388片获得FDA同意开展临床试验
智通财经 · 08:46
海思科(002653.SZ):创新药HSK47388片获得FDA同意开展临床试验
异动快报:海思科(002653)7月10日10点0分触及涨停板
证券之星 · 07-10
异动快报:海思科(002653)7月10日10点0分触及涨停板
西藏板块盘中拉升,海思科涨7.09%
市场透视 · 07-10
西藏板块盘中拉升,海思科涨7.09%
【创新药概念股反复活跃,塞力医疗、康辰药业触及涨停】创新药概念股反复活跃,塞力医疗、康辰药业触及涨停,海思科涨超7%,先达股份、华纳药厂、微芯生物纷纷上涨。
金融界 · 07-10
【创新药概念股反复活跃,塞力医疗、康辰药业触及涨停】创新药概念股反复活跃,塞力医疗、康辰药业触及涨停,海思科涨超7%,先达股份、华纳药厂、微芯生物纷纷上涨。
海思科法定代表人变更为严庞科
金融界 · 07-10
海思科法定代表人变更为严庞科
海思科收盘下跌4.60%,滚动市盈率136.62倍,总市值478.32亿元
金融界 · 07-07
海思科收盘下跌4.60%,滚动市盈率136.62倍,总市值478.32亿元
海思科(002653.SZ)2025年度向特定对象发行股票申请获深交所受理
智通财经 · 07-07
海思科(002653.SZ)2025年度向特定对象发行股票申请获深交所受理
海思科收盘上涨1.68%,滚动市盈率143.21倍,总市值501.39亿元
金融界 · 07-04
海思科收盘上涨1.68%,滚动市盈率143.21倍,总市值501.39亿元
海思科法定代表人变更为严庞科
金融界 · 06-26
海思科法定代表人变更为严庞科
海思科(002653.SZ):HSK47388片新适应症IND申请获受理
智通财经 · 06-24
海思科(002653.SZ):HSK47388片新适应症IND申请获受理
海思科收盘下跌3.01%,滚动市盈率131.12倍,总市值459.05亿元
金融界 · 06-20
海思科收盘下跌3.01%,滚动市盈率131.12倍,总市值459.05亿元
海思科:变更保荐机构为中信证券
公司公告 · 06-19
海思科:变更保荐机构为中信证券
西藏板块盘中跳水,海思科跌1.22%
市场透视 · 06-18
西藏板块盘中跳水,海思科跌1.22%
6月17日海思科跌5.68%,富国精准医疗混合A基金重仓该股
证券之星 · 06-17
6月17日海思科跌5.68%,富国精准医疗混合A基金重仓该股
海思科获得外观设计专利授权:“包装盒(倍长平)”
证券之星 · 06-16
海思科获得外观设计专利授权:“包装盒(倍长平)”
西藏板块盘中跳水,海思科跌1.95%
市场透视 · 06-13
西藏板块盘中跳水,海思科跌1.95%
海思科(002653)股东范秀莲质押1065万股,占总股本0.95%
证券之星 · 06-12
海思科(002653)股东范秀莲质押1065万股,占总股本0.95%
【海思科:HSK47977片获国家药品监督管理局受理】海思科公告,公司于近日收到国家药品监督管理局下发的《受理通知书》,HSK47977片的IND申请获得受理。HSK47977是公司自主研发的全球新口服小分子抗肿瘤药物,拟用于淋巴瘤的治疗。目前,全球尚无同靶点药物进入临床阶段。临床前研究结果显示,HSK47977在体外对人淋巴瘤细胞系展现出明显的增殖抑制作用,在体内异种移植模型中能有效抑制肿瘤生长,表现出较强的靶点选择性和理想的安全窗,有望为淋巴瘤患者提供新的治疗选择。
金融界 · 06-09
【海思科:HSK47977片获国家药品监督管理局受理】海思科公告,公司于近日收到国家药品监督管理局下发的《受理通知书》,HSK47977片的IND申请获得受理。HSK47977是公司自主研发的全球新口服小分子抗肿瘤药物,拟用于淋巴瘤的治疗。目前,全球尚无同靶点药物进入临床阶段。临床前研究结果显示,HSK47977在体外对人淋巴瘤细胞系展现出明显的增殖抑制作用,在体内异种移植模型中能有效抑制肿瘤生长,表现出较强的靶点选择性和理想的安全窗,有望为淋巴瘤患者提供新的治疗选择。
海思科最新公告:公司创新药HSK47388片IND申请获受理
证券之星 · 06-02
海思科最新公告:公司创新药HSK47388片IND申请获受理
中证健康产业指数上涨0.55%,前十大权重包含海思科等
金融界 · 05-30
中证健康产业指数上涨0.55%,前十大权重包含海思科等
加载更多
公司概况
公司名称:
海思科医药集团股份有限公司
所属行业:
医药制造业
上市日期:
2012-01-17
主营业务:
海思科医药集团股份有限公司的主营业务是新药研发、生产制造、推广营销业务。公司的主要产品是创新药环泊酚注射液、苯磺酸克利加巴林胶囊、考格列汀片。海思科以“创新”为内核,获得了行业的高度认可,连续多年荣获“中国创新力医药企业”称号。在2022-2023年中国医药行业最具影响力榜单评选中,海思科荣膺四项殊荣,包括医药商业百强企业、医药制造业百强企业、自主创新先锋企业、守法诚信企业。2024年中国医药研发产品线荣获“最佳工业企业”奖项。
发行价格:
20.00
{"stockData":{"symbol":"002653","market":"SZ","secType":"STK","nameCN":"海思科","latestPrice":46.5,"timestamp":1752562989000,"preClose":45.65,"halted":0,"volume":4025300,"delay":0,"changeRate":0.0186,"floatShares":534999999,"shares":1120000000,"eps":0.3127,"marketStatus":"已收盘","change":0.85,"latestTime":"07-15 15:00:00","open":45.22,"high":47.1,"low":45.21,"amount":186000000,"amplitude":0.0414,"askPrice":46.5,"askSize":47,"bidPrice":46.49,"bidSize":12,"shortable":0,"etf":0,"ttmEps":0.3127,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752629400000},"marketStatusCode":5,"adr":0,"adjPreClose":45.65,"symbolType":"stock","openAndCloseTimeList":[[1752543000000,1752550200000],[1752555600000,1752562800000]],"highLimit":50.22,"lowLimit":41.09,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1119917970,"isCdr":false,"pbRate":12.42,"roa":"--","peRate":148.704829,"roe":"1.13%","epsLYR":0.35,"committee":-0.285714,"marketValue":52076000000,"turnoverRate":0.0075,"status":0,"floatMarketCap":24899000000},"requestUrl":"/m/hq/s/002653","defaultTab":"news","newsList":[{"id":"2551157660","title":"海思科(002653.SZ):创新药HSK47388片获得FDA同意开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2551157660","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551157660?lang=zh_cn&edition=full","pubTime":"2025-07-15 16:46","pubTimestamp":1752569200,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科(002653.SZ)披露近日收到美国食品药品监督管理局(“FDA”)的 Study May Proceed Letter,根据FDA相关规定,经审查,公司2025年5月递交的HSK47388片临床试验申请符合药品注册的有关要求,同意本品开展临床试验。公告称,HSK47388片是公司自主研发的口服、强效、高选择性的药物,拟用于自身免疫疾病的治疗。临床前研究结果显示,HSK47388可以剂量依赖地抑制大鼠炎症反应,同时也表现出了良好的耐受性和较大的安全窗,是一款极具开发潜力的药物,有望为自身免疫疾病患者提供一种新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002653","BK0077","BK0188","BK1161","159992","03347","BK0028","BK1574","BK1141","BK0239","BK0033","BK1576","BK1583","06978"],"gpt_icon":0},{"id":"2550693380","title":"异动快报:海思科(002653)7月10日10点0分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2550693380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550693380?lang=zh_cn&edition=full","pubTime":"2025-07-10 10:05","pubTimestamp":1752113124,"startTime":"0","endTime":"0","summary":"证券之星7月10日盘中消息,10点0分海思科触及涨停板。目前价格46.41,上涨10.0%。其所属行业化学制药目前上涨。领涨股为联环药业。该股为西藏概念,创新药,幽门螺杆菌概念概念热股,当日西藏概念概念上涨1.55%,创新药概念上涨0.97%,幽门螺杆菌概念概念上涨0.88%。7月9日的资金流向数据方面,主力资金净流出654.58万元,占总成交额4.94%,游资资金净流出370.96万元,占总成交额2.8%,散户资金净流入1025.55万元,占总成交额7.74%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000009397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002653","BK0239","BK0077","BK0033","BK0028"],"gpt_icon":0},{"id":"2550985456","title":"西藏板块盘中拉升,海思科涨7.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550985456","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550985456?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:48","pubTimestamp":1752112094,"startTime":"0","endTime":"0","summary":"07月10日,西藏板块盘中拉升,截至09点48分,西藏板块整体指数上涨1.07%,报2193.190点。从个股上来看,该板块的成分股中,海思科涨7.09%,多瑞医药、华钰矿业2只股涨幅超过5%。从资金上来看,截止发稿,西藏板块主力净流入为8881.17万,其中华钰矿业受到资金热捧,主力净流入8301.42万;拉长时间线来看,该板块近20日主力资金净流入-21.92亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710094814a6a0761b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710094814a6a0761b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0077","002653","BK0242","BK0182","BK0033","BK0028","601020","BK0188"],"gpt_icon":0},{"id":"2550660707","title":"【创新药概念股反复活跃,塞力医疗、康辰药业触及涨停】创新药概念股反复活跃,塞力医疗、康辰药业触及涨停,海思科涨超7%,先达股份、华纳药厂、微芯生物纷纷上涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2550660707","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550660707?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:46","pubTimestamp":1752111976,"startTime":"0","endTime":"0","summary":"创新药概念股反复活跃,塞力医疗、康辰药业触及涨停,海思科涨超7%,先达股份、华纳药厂、微芯生物纷纷上涨。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f4ae4484572f275cf3aa38bb605c2821","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/10094651600059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["603590","002653","06978","BK0028","BK0239","688321","BK0188","BK1161","159992","BK0077","BK0033","BK0250","688799","BK1574","603086","BK0229","603716"],"gpt_icon":0},{"id":"2550030664","title":"海思科法定代表人变更为严庞科","url":"https://stock-news.laohu8.com/highlight/detail?id=2550030664","media":"金融界","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550030664?lang=zh_cn&edition=full","pubTime":"2025-07-10 08:17","pubTimestamp":1752106669,"startTime":"0","endTime":"0","summary":"近日,天眼查APP显示,海思科医药集团股份有限公司(简称“海思科”)法定代表人发生变更,从范秀莲变为严庞科。资料显示,海思科医药集团股份有限公司法定代表人为严庞科,成立于2005年,位于山南市,是一家以从事医药制造业为主的企业。企业注册资本111991.797万人民币,实缴资本111991.797万人民币。通过天眼查大数据分析,海思科医药集团股份有限公司共对外投资了20家企业,参与招投标项目31次,知识产权方面有商标信息468条,专利信息65条,此外企业还拥有行政许可14个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/10081751597787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0028","BK0077","BK0033","BK0239","002653","BK0188"],"gpt_icon":0},{"id":"2549814625","title":"海思科收盘下跌4.60%,滚动市盈率136.62倍,总市值478.32亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549814625","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549814625?lang=zh_cn&edition=full","pubTime":"2025-07-07 16:44","pubTimestamp":1751877887,"startTime":"0","endTime":"0","summary":"7月7日,海思科今日收盘42.71元,下跌4.60%,滚动市盈率PE达到136.62倍,总市值478.32亿元。从行业市盈率排名来看,公司所处的化学制药行业市盈率平均54.01倍,行业中值32.80倍,海思科排名第131位。资金流向方面,7月7日,海思科主力资金净流出1256.22万元,近5日总体呈流出状态,5日共流出871.77万元。海思科以“创新”为内核,获得了行业的高度认可,连续多年荣获“中国创新力医药企业”称号。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/07164451530372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0028","BK0077","BK0033","BK0239","002653","BK0188"],"gpt_icon":0},{"id":"2549930901","title":"海思科(002653.SZ)2025年度向特定对象发行股票申请获深交所受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2549930901","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549930901?lang=zh_cn&edition=full","pubTime":"2025-07-07 11:59","pubTimestamp":1751860782,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科(002653.SZ)发布公告,公司于2025年7月4日晚间收到深圳证券交易所(简称“深交所”)出具的《关于受理海思科医药集团股份有限公司向特定对象发行股票申请文件的通知》(深证上审〔2025〕130号)。深交所对公司报送的向特定对象发行股票的申请文件进行了核对,认为申请文件齐备,决定予以受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1314510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002653","BK0028","BK0077","BK0188","BK0033"],"gpt_icon":0},{"id":"2548369388","title":"海思科收盘上涨1.68%,滚动市盈率143.21倍,总市值501.39亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548369388","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548369388?lang=zh_cn&edition=full","pubTime":"2025-07-04 16:47","pubTimestamp":1751618855,"startTime":"0","endTime":"0","summary":"7月4日,海思科今日收盘44.77元,上涨1.68%,滚动市盈率PE达到143.21倍,创15天以来新低,总市值501.39亿元。从行业市盈率排名来看,公司所处的化学制药行业市盈率平均54.93倍,行业中值33.30倍,海思科排名第131位。股东方面,截至2025年3月31日,海思科股东户数9072户,较上次减少3495户,户均持股市值35.28万元,户均持股数量2.76万股。海思科以“创新”为内核,获得了行业的高度认可,连续多年荣获“中国创新力医药企业”称号。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/04164751487286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","002653","BK0239","BK0077","BK0033","BK0028"],"gpt_icon":0},{"id":"2546544347","title":"海思科法定代表人变更为严庞科","url":"https://stock-news.laohu8.com/highlight/detail?id=2546544347","media":"金融界","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546544347?lang=zh_cn&edition=full","pubTime":"2025-06-27 05:46","pubTimestamp":1750974403,"startTime":"0","endTime":"0","summary":"近日,天眼查APP显示,海思科医药集团股份有限公司(简称“海思科”)法定代表人发生变更,从范秀莲变为严庞科。资料显示,海思科医药集团股份有限公司法定代表人为严庞科,成立于2005年,位于山南市,是一家以从事医药制造业为主的企业。企业注册资本111991.797万人民币,实缴资本111991.797万人民币。通过天眼查大数据分析,海思科医药集团股份有限公司共对外投资了20家企业,参与招投标项目30次,知识产权方面有商标信息493条,专利信息63条,此外企业还拥有行政许可12个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/27054651333252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002653","BK0077","BK0033","BK0239","BK0188","BK0028"],"gpt_icon":0},{"id":"2545283067","title":"海思科(002653.SZ):HSK47388片新适应症IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2545283067","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545283067?lang=zh_cn&edition=full","pubTime":"2025-06-24 18:05","pubTimestamp":1750759527,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科(002653.SZ)公告,公司近日收到国家药品监督管理局下发的《受理通知书》,药品名称为:HSK47388片,适应症为:拟用于自身免疫疾病的治疗,申请事项为境内生产药品注册临床试验。公告显示,HSK47388片是公司自主研发的口服、强效、高选择性的药物,拟用于自身免疫疾病的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1309018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海思科(002653.SZ):HSK47388片新适应症IND申请获受理","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0033","BK0077","BK0239","BK0188","002653","BK0028"],"gpt_icon":0},{"id":"2544714101","title":"海思科收盘下跌3.01%,滚动市盈率131.12倍,总市值459.05亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544714101","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544714101?lang=zh_cn&edition=full","pubTime":"2025-06-20 16:44","pubTimestamp":1750409052,"startTime":"0","endTime":"0","summary":"6月20日,海思科今日收盘40.99元,下跌3.01%,滚动市盈率PE达到131.12倍,总市值459.05亿元。从行业市盈率排名来看,公司所处的化学制药行业市盈率平均52.51倍,行业中值29.91倍,海思科排名第131位。股东方面,截至2025年3月31日,海思科股东户数9072户,较上次减少3495户,户均持股市值35.28万元,户均持股数量2.76万股。海思科以“创新”为内核,获得了行业的高度认可,连续多年荣获“中国创新力医药企业”称号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/20164451200144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK0028","002653","BK0188","BK0077","BK0033"],"gpt_icon":0},{"id":"2544152694","title":"海思科:变更保荐机构为中信证券","url":"https://stock-news.laohu8.com/highlight/detail?id=2544152694","media":"公司公告","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544152694?lang=zh_cn&edition=full","pubTime":"2025-06-19 16:09","pubTimestamp":1750320542,"startTime":"0","endTime":"0","summary":"海 思科 公告,因2025年度向特定对象发行A股股票相关议案的审议通过,公司聘请 中信证券 担任本次发行的保荐机构,原保荐机构华泰联合证券自签署保荐协议之日起不再履行持续督导职责。中信证券委派沈子权先生、王琦先生担任持续督导保荐代表人,并完成尚未完成的督导工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619171037a4b241d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619171037a4b241d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0028","LU1997245094.SGD","LU1328615791.USD","BK0183","BK0012","LU1655091616.SGD","LU1997245177.USD","BK0196","LU0405327148.USD","LU1064131003.USD","BK0033","002653","BK0239","LU2495084118.USD","600030","LU2289578879.USD","LU1064130708.USD","LU1997244956.HKD","BK0276","BK0077","LU2148510915.USD","LU0405327494.USD"],"gpt_icon":0},{"id":"2544594832","title":"西藏板块盘中跳水,海思科跌1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2544594832","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544594832?lang=zh_cn&edition=full","pubTime":"2025-06-18 10:08","pubTimestamp":1750212522,"startTime":"0","endTime":"0","summary":"06月18日,西藏板块盘中跳水,截至10点08分,西藏板块整体指数下跌2.03%,报2036.630点。从个股上来看,该板块的成分股中,海思科跌1.22%,西藏药业、西藏旅游、多瑞医药跌幅居前。从资金上来看,截止发稿,西藏板块主力净流入为-1.75亿,其中华林证券受到资金热捧,主力净流入1306.11万;拉长时间线来看,该板块近20日主力资金净流入-15.10亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025061810084297843e15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025061810084297843e15&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600749","BK0239","BK0028","002653","BK0033","BK0188","600211","BK0077"],"gpt_icon":0},{"id":"2544195189","title":"6月17日海思科跌5.68%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2544195189","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544195189?lang=zh_cn&edition=full","pubTime":"2025-06-17 16:26","pubTimestamp":1750148806,"startTime":"0","endTime":"0","summary":"证券之星消息,6月17日海思科跌5.68%,收盘报42.69元,换手率1.03%,成交量5.52万手,成交额2.4亿元。重仓海思科的前十大公募基金请见下表:该股最近90天内共有9家机构给出评级,买入评级9家;过去90天内机构目标均价为54.61。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共48家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为37.46亿元,最新净值3.2864,较上一交易日下跌0.32%,近一年上涨40.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061700024250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0077","BK0239","BK0033","002653"],"gpt_icon":0},{"id":"2544460056","title":"海思科获得外观设计专利授权:“包装盒(倍长平)”","url":"https://stock-news.laohu8.com/highlight/detail?id=2544460056","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544460056?lang=zh_cn&edition=full","pubTime":"2025-06-17 03:10","pubTimestamp":1750101021,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示海思科新获得一项外观设计专利授权,专利名为“包装盒(倍长平)”,专利申请号为CN202430411451.9,授权日为2025年6月17日。今年以来海思科新获得专利授权3个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061700001712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002653","BK0028","BK0033","BK0077","BK0188"],"gpt_icon":0},{"id":"2543357891","title":"西藏板块盘中跳水,海思科跌1.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2543357891","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543357891?lang=zh_cn&edition=full","pubTime":"2025-06-13 10:48","pubTimestamp":1749782918,"startTime":"0","endTime":"0","summary":"06月13日,西藏板块盘中跳水,截至10点48分,西藏板块整体指数下跌2.05%,报2055.660点。从个股上来看,该板块的成分股中,海思科跌1.95%,华林证券、西藏矿业、西藏珠峰跌幅居前。从资金上来看,截止发稿,西藏板块主力净流入为-9414.34万,其中易明医药受到资金热捧,主力净流入3375.16万;拉长时间线来看,该板块近20日主力资金净流入-17.64亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613104838951a6279&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613104838951a6279&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","002653","BK0239","BK0077","BK0187","BK0033","BK0242","600338","BK0028"],"gpt_icon":0},{"id":"2543854961","title":"海思科(002653)股东范秀莲质押1065万股,占总股本0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2543854961","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543854961?lang=zh_cn&edition=full","pubTime":"2025-06-13 00:24","pubTimestamp":1749745467,"startTime":"0","endTime":"0","summary":"证券之星消息,海思科6月13日公开信息显示,股东范秀莲向国金证券股份有限公司合计质押1065.0万股,占总股本0.95%。质押详情见下表:截止本公告日,股东王俊民已累计质押股份8844.0万股,占其持股总数的22.13%,股东范秀莲已累计质押股份4611.0万股,占其持股总数的21.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061300000067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002653","BK0188","BK0239","BK0033","BK0028"],"gpt_icon":0},{"id":"2542802829","title":"【海思科:HSK47977片获国家药品监督管理局受理】海思科公告,公司于近日收到国家药品监督管理局下发的《受理通知书》,HSK47977片的IND申请获得受理。HSK47977是公司自主研发的全球新口服小分子抗肿瘤药物,拟用于淋巴瘤的治疗。目前,全球尚无同靶点药物进入临床阶段。临床前研究结果显示,HSK47977在体外对人淋巴瘤细胞系展现出明显的增殖抑制作用,在体内异种移植模型中能有效抑制肿瘤生长,表现出较强的靶点选择性和理想的安全窗,有望为淋巴瘤患者提供新的治疗选择。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542802829","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542802829?lang=zh_cn&edition=full","pubTime":"2025-06-09 17:12","pubTimestamp":1749460349,"startTime":"0","endTime":"0","summary":"海思科公告,公司于近日收到国家药品监督管理局下发的《受理通知书》,HSK47977片的IND申请获得受理。HSK47977是公司自主研发的全球新口服小分子抗肿瘤药物,拟用于淋巴瘤的治疗。目前,全球尚无同靶点药物进入临床阶段。临床前研究结果显示,HSK47977在体外对人淋巴瘤细胞系展现出明显的增殖抑制作用,在体内异种移植模型中能有效抑制肿瘤生长,表现出较强的靶点选择性和理想的安全窗,有望为淋巴瘤患者提供新的治疗选择。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/09171250949736.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0033","BK0077","BK0239","BK0188","002653","BK0028"],"gpt_icon":0},{"id":"2540476323","title":"海思科最新公告:公司创新药HSK47388片IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2540476323","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540476323?lang=zh_cn&edition=full","pubTime":"2025-06-02 15:50","pubTimestamp":1748850612,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)公告称,公司于近日收到国家药品监督管理局下发的《受理通知书》,HSK47388片为公司自主研发的口服、强效、高选择性的药物,拟用于自身免疫疾病的治疗。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060200001523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","159992","BK1574","06978","BK0033","BK0077","BK0188","BK0028","002653"],"gpt_icon":0},{"id":"2539275633","title":"中证健康产业指数上涨0.55%,前十大权重包含海思科等","url":"https://stock-news.laohu8.com/highlight/detail?id=2539275633","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539275633?lang=zh_cn&edition=full","pubTime":"2025-05-30 22:39","pubTimestamp":1748615986,"startTime":"0","endTime":"0","summary":"金融界5月30日消息,上证指数低开低走,中证健康产业指数 上涨0.55%,报1178.92点,成交额391.66亿元。数据统计显示,中证健康产业指数近一个月上涨3.59%,近三个月上涨4.97%,年至今上涨3.36%。据了解,中证健康产业指数选取医疗保健、食品安全、环保等三大产业中市值最大的100只证券作为指数样本,并以等权重加权。从中证健康产业指数持仓样本的行业来看,医药卫生占比39.34%、主要消费占比29.81%、工业占比23.61%、公用事业占比7.24%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/30223950786105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002653","BK0239","BK0188","BK0077","BK0028","BK0033"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752574209425,"stockEarnings":[{"period":"1week","weight":0.0688},{"period":"1month","weight":-0.0172},{"period":"3month","weight":0.0132},{"period":"6month","weight":0.4463},{"period":"1year","weight":0.4825},{"period":"ytd","weight":0.3832}],"compareEarnings":[{"period":"1week","weight":0.0134},{"period":"1month","weight":0.0422},{"period":"3month","weight":0.0771},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1846},{"period":"ytd","weight":0.0501}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海思科医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9072人(较上一季度减少27.81%)","perCapita":"59023股","listingDate":"2012-01-17","address":"西藏自治区山南市乃东区泽当镇三湘大道17号","registeredCapital":"111991万元","survey":" 海思科医药集团股份有限公司的主营业务是新药研发、生产制造、推广营销业务。公司的主要产品是创新药环泊酚注射液、苯磺酸克利加巴林胶囊、考格列汀片。海思科以“创新”为内核,获得了行业的高度认可,连续多年荣获“中国创新力医药企业”称号。在2022-2023年中国医药行业最具影响力榜单评选中,海思科荣膺四项殊荣,包括医药商业百强企业、医药制造业百强企业、自主创新先锋企业、守法诚信企业。2024年中国医药研发产品线荣获“最佳工业企业”奖项。","listedPrice":20},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海思科,002653,海思科股票,海思科股票老虎,海思科股票老虎国际,海思科行情,海思科股票行情,海思科股价,海思科股市,海思科股票价格,海思科股票交易,海思科股票购买,海思科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}